Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study-Reference-Cited by-同舟云学术

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Published:2015-12-09 Issue:7 Volume:22 Page:1572-1582
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Niemann Carsten U.,Herman Sarah E.M.,Maric Irina,Gomez-Rodriguez Julio,Biancotto Angelique,Chang Betty Y.,Martyr Sabrina,Stetler-Stevenson Maryalice,Yuan Constance M.,Calvo Katherine R.,Braylan Raul C.,Valdez Janet,Lee Yuh Shan,Wong Deanna H.,Jones Jade,Sun Clare,Marti Gerald E.,Farooqui Mohammed Z.H.,Wiestner Adrian

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma;Scientific Reports;2024-09-11

2. Management of infections for patient treated with ibrutinib in clinical practice;Frontiers in Oncology;2024-09-10

3. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

4. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia;Leukemia Research;2024-08

5. Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis;Expert Opinion on Pharmacotherapy;2024-07-23